Enhancing Immune Response and Heterosubtypic Protection Ability of Inactivated H7N9 Vaccine by Using STING Agonist as a Mucosal Adjuvant

Enhancing Immune Response and Heterosubtypic Protection Ability of Inactivated H7N9 Vaccine by Using STING Agonist as a Mucosal Adjuvant

Influenza vaccines for H7N9 subtype have shown low immunogenicity in human clinical trials. Using novel adjuvants might represent the optimal available option in vaccine development. In this study, we demonstrated that the using of the STING agonist cGAMP as a mucosal adjuvant is effective in enhanc...

Full description

Bibliographic Details
Main Authors: Jian Luo, Xu-ping Liu, Fei-fei Xiong, Fei-xia Gao, Ying-lei Yi, Min Zhang, Ze Chen, Wen-song Tan
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-09-01
Series:Frontiers in Immunology
Subjects:
H7N9
whole viron vaccine
STING
mucosal adjuvant
cross protection
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2019.02274/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2019.02274/full

Similar Items